Akari Therapeutics, Plc Net Change in Cash
Akari Therapeutics, Plc (AKTX) reported Net Change in Cash of $2.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-13
- Akari Therapeutics, Plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$2.44M.
- Akari Therapeutics, Plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$17.00K.
- Akari Therapeutics, Plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$2.54M.
- Akari Therapeutics, Plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$1.67M.
- Akari Therapeutics, Plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $2.60M.
- Akari Therapeutics, Plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$1.19M.
- Akari Therapeutics, Plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$9.40M, a 341.84% decline from fiscal 2022.
- Akari Therapeutics, Plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $3.89M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.49M 10-Q · filed 2026-08-13 | |||||
| 2026-03-31 | -$2.44M 10-Q · filed 2026-05-19 | |||||
| 2025-12-31 | $2.60M 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | -$115.00K 10-Q · filed 2025-11-13 | |||||
| 2025-06-30 | $112.00K 10-Q · filed 2026-08-13 | |||||
| 2025-03-31 | -$17.00K 10-Q · filed 2026-05-19 | |||||
| 2024-12-31 | -$1.19M 10-K · filed 2026-03-30 | |||||
| 2024-09-30 | -$1.60M 10-Q · filed 2025-11-13 | |||||
| 2024-06-30 | $332.00K 10-Q · filed 2025-08-13 | |||||
| 2024-03-31 | -$2.54M 10-Q · filed 2025-05-14 | |||||
| 2023-12-31 | -$9.40M 10-K · filed 2025-04-15 | |||||
| 2023-09-30 | -$8.52M 10-Q · filed 2024-11-19 | |||||
| 2023-06-30 | -$6.07M 10-Q · filed 2024-08-19 | -$6.07M 6-K · filed 2023-09-29 | ||||
| 2023-03-31 | -$1.67M 10-Q · filed 2024-05-15 | |||||
| 2022-12-31 | $3.89M 10-K · filed 2024-03-29 | $3.89M 20-F · filed 2023-05-01 | ||||
| 2022-06-30 | -$1.21M 6-K · filed 2023-09-29 | |||||
| 2021-12-31 | -$4.69M 20-F · filed 2023-05-01 | |||||
| 2021-06-30 | -$10.26M 6-K · filed 2022-09-27 | |||||
| 2020-12-31 | $8.32M 20-F · filed 2023-05-01 | |||||
| 2020-09-30 | $6.59M 20-F · filed 2021-04-21 | |||||
| 2020-06-30 | $7.01M 6-K · filed 2021-09-22 | |||||
| 2020-03-31 | $2.09M 20-F · filed 2021-04-21 | |||||
| 2019-12-31 | -$236.28K 20-F · filed 2022-05-16 | |||||
| 2019-09-30 | $300.70K 20-F · filed 2021-04-21 | |||||
| 2019-06-30 | -$3.21M 20-F · filed 2021-04-21 | |||||
| 2019-03-31 | $325.51K 20-F · filed 2021-04-21 | |||||
| 2018-12-31 | -$22.28M 20-F · filed 2021-04-21 | |||||
| 2018-06-30 | -$12.66M 6-K · filed 2019-08-29 | |||||
| 2017-12-31 | -$5.99M 20-F · filed 2020-03-31 | |||||
| 2016-12-31 | -$34.82M 20-F · filed 2019-04-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |